Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease
- 1 November 1996
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 2 (11) , 1230-1235
- https://doi.org/10.1038/nm1196-1230
Abstract
Alzheimer's disease is a progressive and incurable disease whose prevalence increases dramatically with age. A biochemical marker for monitoring the onset and progression of the disease would be a valuable tool for disease management. In addition, such a marker might be used as an end point in clinical intervention protocols. Here we provide evidence that the soluble form of the iron binding protein p97 is found in elevated amounts in the serum of Alzheimer's patients compared with healthy controls. This biochemical marker has the potential for identifying subjects afflicted with the disease and possibly for monitoring the onset and longitudinal progression of the disease.Keywords
This publication has 44 references indexed in Scilit:
- The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)Science, 1996
- Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 1995
- Response : Zinc and Alzheimer's DiseaseScience, 1995
- Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's diseaseNature, 1995
- Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor ProteinJournal of Neurochemistry, 1995
- Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's diseaseAnnals of Neurology, 1994
- Controlled release process to recover heterologous glycosylphosphatidylinositol membrane anchored proteins from CHO cellsBiotechnology & Bioengineering, 1993
- A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's DiseaseScience, 1991
- The molecular pathology of Alzheimer's diseaseNeuron, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984